Nancy Lin, MD: Clinical Trials

6 trials sponsored by Nancy Lin, MD, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 recruiting, 1 terminated. 4 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Recruiting 1, Terminated 1
Phase 12Completed 2

Follow Nancy Lin, MD: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Datopotamab Deruxtecan - Breast Cancer, Breast Cancer Female
Phase 2RecruitingNancy Lin, MD582024-01-082026-08-06
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB - HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
Phase 2CompletedNancy Lin, MD192018-05-212026-08-21
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Taselisib, Trastuzumab emtansine, Pertuzumab - Metastatic Breast Cancer, Recurrent Breast Cancer
Phase 1CompletedNancy Lin, MD682015-04-202026-09-24
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
ZK219477 - Breast Cancer, CNS Disease
Phase 2TerminatedNancy Lin, MD152007-07-012013-03-14
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Lapatinib, Herceptin - Breast Cancer
Phase 2CompletedNancy Lin, MD872007-05-142024-12-19
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
Lapatinib, Whole Brain Radiation, Herceptin - Breast Cancer, Brain Metastases
Phase 1CompletedNancy Lin, MD352007-04-012014-05-22

Conditions studied

Breast Neoplasms (5)  ·  Brain Neoplasms (2)  ·  Central Nervous System Diseases (1)  ·  Triple Negative Breast Neoplasms (1)

Interventions

Trastuzumab (4)  ·  Lapatinib (2)  ·  pertuzumab (2)  ·  2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1)  ·  Ado-Trastuzumab Emtansine (1)  ·  Paclitaxel (1)  ·  atezolizumab (1)  ·  sagopilone (1)

Countries

United States (6)

Results publications

PMID 26169615